. Safe Harbor Statement Ironwood uses non-GAAP financial measures in this presentation, which should be considered only a supplement to, and not a substitute for or superior to, GAAP measures. Refer to the Reconciliation of Non-GAAP Financial Measures to GAAP Results table and to the Reconciliation of Adjusted EBITDA to GAAP net income table and related footnotes on pages 14 and 15 of this presentation. Further, Ironwood considers the net profit for the U.S. LINZESS brand collaboration with AbbVie in assess ...

Trulance (4%) Ibsrela (0%) Volume 1 IQVIA NPA Week Ending November 18, 2022. Strong LINZESS new-to-brand volume and 90-day prescriptions are key indicators of future growth potential 1 IQVIA Patient Insights, Q3 2022. 2 IQVIA Weekly NPA October 2022. 3 IQVIA Quantity Frequency October 2022. LINZESS NBRx Volume Growth1 17 LINZESS 90-Day Prescription ~21%2 120,000 125,000 130,000 135,000 140,000 Q3 2021 Q3 2022 +9% Y/Y 34 35 36 37 38 39 40 41 42 43 44 Average TRx fill size 3 The natural history of Primary Bil ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or oth ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2022 Results Conference Call November 3, 2022 8:30 AM ET Company Participants Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Matt Roache - Director of Investor Relations Conference Call Participants Boris Peaker - Cowen Daniel Wolle - JPMorgan Tim Chiang - Capital One Operator Hello. My name is Lisa, and I will be your conference operator today. At this time, I would like to welcome everyone ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Representatives Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Matt Roache - Director of Investor Relations Conference Call Participants David Amsellem - Piper Sandler Operator Good morning. My name is Stephanie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other ju ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Matt Roache - Director, Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Participants Hannah Monigatti - JPMorgan David Amsellem - Piper Sandler Tim Chiang - Northland Capital Markets Boris Peaker - Cowen and Company Operator Good morning. My name is Joseph and I will be your conference ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 04-3404176 (St ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2021 Earnings Conference Call February 17, 2022 8:30 AM ET Company Participants Matt Roache - Director of IR Thomas McCourt - CEO Michael Shetzline - CMO and Head of R&D Sravan K. Emany - CFO Conference Call Participants Boris Peaker - Cowen & Company Eric Joseph - JPMorgan Timothy Chiang - Northland Capital Unidentified Analyst - Wells Fargo Operator Ladies and gentlemen, good morning. My name is Abby and I will be your conference operator today. At this time ...